Galleon Bio has developed a novel topical treatment, CB400, specifically designed to address several unmet needs in the management of psoriasis and other dermatological conditions, including atopic dermatitis. The preclinical and clinical development programs to achieve regulatory approval are currently designed.
CB400 is a patented combination of three known chemical entities displaying anti oxidative, anti-inflammatory and immunomodulatory activity. Individual therapeutic use of these components is supported with abundant published clinical data and real life utilization experience, which have demonstrated an excellent safety and efficacy profile across multiple conditions, especially dermatological ones.
During development, CB400 was tested in human stem cell systems and demonstrated remarkable immunomodulatory and anti-inflammatory activity similar to known immunomodulatory agents. CB400 modulates pathways and biomarkers with established role in psoriasis, targeted by approved systemic psoriasis therapies.
Based on existing evidence, CB400 has the promise to be a unique product introduction with multiple incremental effects inherited from its triple synthesis. It can become a valuable solution to meet the psoriasis management unmet needs for patients, health care providers and payers.
CB400 promises to be a well tolerated, safer, effective, and cost-effective therapy that will improve the management of mild and moderate patients and will delay the onset of invasive and costlier systemic therapy and will alleviate some of the safety concerns associated with its long term use.
CB400 may deliver superior outcomes for patients, may increase patient satisfaction, therapy access and compliance and may generate significant savings for payers.
